Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 and Famitinib in Resectable Mucosal Melanoma
NCT07517653Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of retlirafusp alfa, famitinib in mucosal melanoma (MM), sponsored by Zhongshan Hospital, Fudan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfafamitinib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT07517653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517653.